Henry H. Armstrong Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.43M | Sell |
17,623
-100
| -0.6% | -$21.5K | 0.43% | 19 |
|
|
2026
Q1 | $3.85M | Sell |
17,723
-18
| -0.1% | -$3.99K | 0.39% | 17 |
|
|
2025
Q4 | $4.05M | Hold |
17,741
| – | – | 0.38% | 17 |
|
|
2025
Q3 | $4.11M | Hold |
17,741
| – | – | 0.37% | 19 |
|
|
2025
Q2 | $3.29M | Sell |
17,741
-70
| -0.4% | -$13K | 0.31% | 19 |
|
|
2025
Q1 | $3.73M | Hold |
17,811
| – | – | 0.36% | 18 |
|
|
2024
Q4 | $3.17M | Sell |
17,811
-92
| -0.5% | -$16.9K | 0.32% | 19 |
|
|
2024
Q3 | $3.54M | Sell |
17,903
-790
| -4% | -$147K | 0.34% | 19 |
|
|
2024
Q2 | $3.21M | Buy |
18,693
+18
| +0.1% | +$2.98K | 0.32% | 19 |
|
|
2024
Q1 | $3.4M | Sell |
18,675
-400
| -2% | -$68.9K | 0.33% | 19 |
|
|
2023
Q4 | $2.96M | Sell |
19,075
-4,000
| -17% | -$583K | 0.31% | 19 |
|
|
2023
Q3 | $3.44M | Hold |
23,075
| – | – | 0.39% | 17 |
|
|
2023
Q2 | $3.11M | Sell |
23,075
-1,105
| -5% | -$162K | 0.34% | 20 |
|
|
2023
Q1 | $3.85M | Sell |
24,180
-830
| -3% | -$127K | 0.47% | 15 |
|
|
2022
Q4 | $4.04M | Hold |
25,010
| – | – | 0.5% | 18 |
|
|
2022
Q3 | $3.36M | Hold |
25,010
| – | – | 0.46% | 19 |
|
|
2022
Q2 | $3.83M | Buy |
25,010
+41
| +0.2% | +$6.26K | 0.48% | 18 |
|
|
2022
Q1 | $4.05M | Buy |
24,969
+211
| +0.9% | +$30.6K | 0.43% | 18 |
|
|
2021
Q4 | $3.35M | Hold |
24,758
| – | – | 0.35% | 22 |
|
|
2021
Q3 | $2.67M | Buy |
24,758
+600
| +2% | +$68.6K | 0.31% | 23 |
|
|
2021
Q2 | $2.72M | Sell |
24,158
-50
| -0.2% | -$5.63K | 0.31% | 24 |
|
|
2021
Q1 | $2.62M | Hold |
24,208
| – | – | 0.32% | 25 |
|
|
2020
Q4 | $2.59M | Hold |
24,208
| – | – | 0.34% | 24 |
|
|
2020
Q3 | $2.12M | Buy |
24,208
+142
| +0.6% | +$13.4K | 0.29% | 25 |
|
|
2020
Q2 | $2.36M | Sell |
24,066
-200
| -0.8% | -$17.6K | 0.35% | 24 |
|
|
2020
Q1 | $1.85M | Sell |
24,266
-175
| -0.7% | -$14.9K | 0.31% | 24 |
|
|
2019
Q4 | $2.16M | Hold |
24,441
| – | – | 0.31% | 27 |
|
|
2019
Q3 | $1.85M | Hold |
24,441
| – | – | 0.3% | 23 |
|
|
2019
Q2 | $1.78K | Hold |
24,441
| – | – | 0.24% | 26 |
|
|
2019
Q1 | $1.97M | Hold |
24,441
| – | – | 0.3% | 27 |
|
|
2018
Q4 | $2.25M | Sell |
24,441
-800
| -3% | -$70.4K | 0.37% | 23 |
|
|
2018
Q3 | $2.39M | Hold |
25,241
| – | – | 0.37% | 24 |
|
|
2018
Q2 | $2.34M | Sell |
25,241
-200
| -0.8% | -$19.5K | 0.4% | 22 |
|
|
2018
Q1 | $2.38M | Hold |
25,441
| – | – | 0.39% | 22 |
|
|
2017
Q4 | $2.46M | Buy |
25,441
+600
| +2% | +$56.5K | 0.41% | 22 |
|
|
2017
Q3 | $2.21M | Sell |
24,841
-444
| -2% | -$33.8K | 0.4% | 23 |
|
|
2017
Q2 | $1.83M | Hold |
25,285
| – | – | 0.35% | 25 |
|
|
2017
Q1 | $1.65M | Sell |
25,285
-1,900
| -7% | -$119K | 0.31% | 28 |
|
|
2016
Q4 | $1.7M | Sell |
27,185
-500
| -2% | -$30.5K | 0.35% | 25 |
|
|
2016
Q3 | $1.75M | Buy |
27,685
+694
| +3% | +$44.9K | 0.34% | 25 |
|
|
2016
Q2 | $1.67M | Hold |
26,991
| – | – | 0.34% | 23 |
|
|
2016
Q1 | $1.54M | Hold |
26,991
| – | – | 0.32% | 23 |
|
|
2015
Q4 | $1.6M | Sell |
26,991
-50
| -0.2% | -$2.88K | 0.31% | 24 |
|
|
2015
Q3 | $1.47M | Hold |
27,041
| – | – | 0.3% | 22 |
|
|
2015
Q2 | $1.82M | Hold |
27,041
| – | – | 0.44% | 19 |
|
|
2015
Q1 | $1.58M | Buy |
27,041
+50
| +0.2% | +$3.02K | 0.35% | 21 |
|
|
2014
Q4 | $1.77M | Sell |
26,991
-600
| -2% | -$37.8K | 0.38% | 20 |
|
|
2014
Q3 | $1.59M | Hold |
27,591
| – | – | 0.36% | 20 |
|
|
2014
Q2 | $1.56M | Hold |
27,591
| – | – | 0.37% | 21 |
|
|
2014
Q1 | $1.42M | Sell |
27,591
-1,520
| -5% | -$76.8K | 0.35% | 21 |
|
|
2013
Q4 | $1.54M | Hold |
29,111
| – | – | 0.32% | 20 |
|
|
2013
Q3 | $1.3M | Hold |
29,111
| – | – | 0.35% | 20 |
|
|
2013
Q2 | $1.2M | Buy |
+29,111
| New | +$1.27M | 0.33% | 21 |
|
Other funds holding ABBV
ECSS
ATO
Henry H. Armstrong Associates's ABBV Position: Q2 2026 in Review
Henry H. Armstrong Associates reduced its AbbVie (ABBV) stake by 0.56% in Q2 2026, selling an estimated $21.5K and leaving 17,623 shares worth $4.43M. The position accounts for 0.43% of the portfolio, ranked #19.
Henry H. Armstrong Associates first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Henry H. Armstrong Associates held 17,623 shares of AbbVie worth $4.43M as of Q2 2026.
- Henry H. Armstrong Associates sold 100 AbbVie shares in Q2 2026, an estimated $21.5K.
- AbbVie made up 0.43% of Henry H. Armstrong Associates's portfolio in Q2 2026, its #19 holding.
- Henry H. Armstrong Associates first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
- 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Henry H. Armstrong Associates's 13F filing for Q2 2026, filed 7 Jul 2026.